In this clinical overview, Dr. Patrick Nemechek discusses how he uses rifaximin (spoken as “raxin/refax”) to help reduce inflammation that he believes is commonly driven by intestinal bacterial overgrowth. In his framework, the goal is not simply to “block inflammation” with broad anti-inflammatory drugs, but to identify where inflammatory signaling is coming from and work to turn it off at its source.
He notes that many chronic medical conditions are associated with elevated inflammatory cytokines in the bloodstream and/or in the brain. From his perspective, a major contributor to this inflammatory load is the intestinal tract—particularly the small intestine—when bacterial balance is disrupted.
This article summarizes his reasoning, the clinical patterns he reports seeing, and how he describes using rifaximin within a broader autonomic recovery protocol.
Medical disclaimer
Want to Learn More About POTS and Autonomic Dysfunction?
Download Dr. Nemechek’s free POTS/PANS/PANDAS eBook for a deeper explanation of autonomic dysfunction, inflammation, and recovery.
This content is for general education and is a summary of Dr. Nemechek’s statements from the referenced video. It is not medical advice and is not a substitute for individualized care from your clinician. Do not start, stop, or change any medication or supplement without guidance from a qualified healthcare professional.
Why Dr. Nemechek focuses on the gut as a major inflammation source
Dr. Nemechek contrasts a common medical approach—using medications such as steroids to “lower inflammation”—with what he considers a safer and more durable strategy: finding what is provoking the inflammatory response and reducing that trigger. In his view, the largest source of inflammation in many patients comes from the intestinal tract, particularly from overgrowth of bacteria in the small intestine.
He uses the term SIBO (small intestinal bacterial overgrowth) and also references the broader term dysbiosis, noting that many researchers prefer “dysbiosis” to avoid debates over strict SIBO definitions while still acknowledging that the gut bacteria are “off.” He also highlights the frequent reporting of “leaky gut,” which he refers to using the clinical term intestinal permeability.
Intestinal permeability and immune activation
Dr. Nemechek emphasizes that a large portion of the immune system is positioned close to the small intestine—he describes it as about 70% of the entire immune system within a millimeter or two of the small intestine. In his explanation, when material “leaks” through the small intestine into surrounding tissue, immune cells can respond aggressively to fragments that are not recognized as the body’s own tissue—whether bacterial fragments or food fragments.
In this model, that immune activation can lead to a significant release of inflammatory chemicals, contributing to a wide range of inflammatory conditions. He adds that other inflammation sources exist, but frames gut-driven immune activation as especially important because of the density of immune tissue adjacent to the small intestine.
Recognizing SIBO/leaky gut: symptoms may be subtle
One practical point Dr. Nemechek stresses is that not everyone with suspected SIBO has obvious intestinal complaints. He states that, in his experience and as suggested by some literature, about a quarter to a third of patients may have minimal or no intestinal symptoms. Patients may report they are “fine,” yet still demonstrate patterns consistent with bacterial overgrowth and intestinal permeability.
He gives an example from his clinical interviews: patients who cannot tolerate tomatoes or spices. He describes food intolerance as a typical sign of “leaky gut” associated with bacterial overgrowth, and notes you do not necessarily need prominent GI symptoms for this process to be active.
Why rifaximin: a long-standing tool for bacterial overgrowth-related illness
Dr. Nemechek describes rifaximin as a key medication for controlling bacterial overgrowth–driven inflammation. He points out that the connection between bacterial overgrowth and serious illness has been recognized for decades, citing the example of adults with severe liver disease who develop bacterial overgrowth and may experience hepatic encephalopathy. In his description, rifaximin has been a widely used medication for this for many years—though he suggests some clinicians may not view it through the lens of SIBO even when the underlying issue overlaps.
Standard short-course regimens he references
He outlines commonly used rifaximin approaches:
- Twice daily for 10 days as a typical starting regimen in his practice.
- He mentions an IBS-diarrhea study where three times daily for 14 days was “a little bit better,” but states he still typically starts with twice daily for 10 days.
He also makes a practical point: if a prescription is written as three times daily for 14 days, the total tablets can effectively cover two rounds of a twice-daily-for-10-days strategy, which he describes as economically helpful for some patients.
Relapse is common: “SIBO is more of a structural problem”
A central theme in Dr. Nemechek’s clinical framing is that treating bacterial overgrowth is often not like treating pneumonia (treat once and it’s gone). He says SIBO tends to be relapsing because the intestinal tract may not be able to maintain normal bacterial organization over time. In his explanation, you can “clear the bacteria out,” but if the intestinal tract is moving too slowly, relapse is likely—sometimes quickly, sometimes months later.
He emphasizes that when patients say rifaximin “worked briefly” or “didn’t work,” the issue may be rapid relapse rather than true non-response.
How he describes longer, continuous use in more disabled patients
Dr. Nemechek reports that in patients who are “really sick” or more disabled—he gives the example of people “beat up” after COVID with significant neurological dysfunction—he may use rifaximin in a non-stop fashion at twice daily for an extended period. He describes continuing it for 4, 6, or 8 months, depending on disability level, with the goal of generating more recovery before stopping.
He then describes a typical pattern after stopping: patients may “coast,” and many can recognize when relapse occurs. Once patients are further out and more stable, he says many adults can go several months before relapsing again, and then may only need 10 days at a time during relapse episodes.
Timing expectations: neurologic improvement may lag behind inflammation control
Dr. Nemechek cautions that patients may not feel better immediately, especially regarding neurological symptoms. He states that neurological recovery often takes two to three months to become noticeably improved. In his model, inflammation needs to be controlled for that duration before a patient is likely to observe meaningful neurologic change—another reason he believes short courses may not be sufficient for more severe cases.
Rifaximin as one part of his broader autonomic recovery framework
In the video, Dr. Nemechek places rifaximin within a larger protocol, which he describes (in adults) as including:
- Rifaximin
- High-DHA fish oil
- Olive oil
- For the majority of patients, a vagal stimulator (he references a device via Nemechek Technologies)
He also comments that some clinicians are uncomfortable prescribing rifaximin for these indications, and that some patients seek his clinic for initial workup and to establish a plan, with follow-up visits over time.
Key takeaway from his perspective: if rifaximin doesn’t appear to help early on, consider the possibility of rapid relapse and the longer time required for neurologic improvement—rather than assuming the approach has failed.
